X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (142) 142
hiv infections - drug therapy (110) 110
infectious diseases (104) 104
male (85) 85
adult (83) 83
female (79) 79
immunology (73) 73
hiv (65) 65
anti-hiv agents - therapeutic use (62) 62
hiv infections - virology (58) 58
middle aged (53) 53
aids (51) 51
viral load (51) 51
virology (51) 51
drug therapy (50) 50
hiv infection (50) 50
clinical trials (46) 46
human immunodeficiency virus--hiv (44) 44
research (44) 44
antiretroviral drugs (40) 40
cd4 lymphocyte count (40) 40
antiretroviral therapy (38) 38
hiv-1 - drug effects (38) 38
hiv infections - immunology (36) 36
microbiology (36) 36
antiviral agents (35) 35
double-blind method (35) 35
drug therapy, combination (35) 35
anti-hiv agents - administration & dosage (33) 33
rna, viral - blood (32) 32
therapy (32) 32
rna (31) 31
viruses (31) 31
treatment outcome (30) 30
hiv-1 - genetics (29) 29
antiretrovirals (28) 28
hiv 1 (27) 27
hiv-1 (27) 27
efavirenz (26) 26
hiv/aids (25) 25
protease inhibitors (25) 25
anti-hiv agents - adverse effects (24) 24
care and treatment (24) 24
dosage and administration (24) 24
health aspects (23) 23
abridged index medicus (22) 22
aids/hiv (22) 22
medicine, general & internal (22) 22
infection (21) 21
reverse transcriptase inhibitors - therapeutic use (21) 21
adolescent (19) 19
anti-hiv agents - pharmacology (19) 19
lamivudine (19) 19
aged (17) 17
drug resistance, viral (17) 17
follow-up studies (17) 17
indinavir (17) 17
zidovudine (17) 17
ccr5 receptor antagonists (16) 16
immunodeficiency-virus-infection (16) 16
initial treatment (16) 16
lamivudine - therapeutic use (16) 16
ritonavir (16) 16
time factors (16) 16
usage (16) 16
young adult (16) 16
drug resistance (15) 15
hiv-1 infection (15) 15
pharmacology & pharmacy (15) 15
acquired immune deficiency syndrome--aids (14) 14
clinical-trials (14) 14
maraviroc (14) 14
patient outcomes (14) 14
prospective studies (14) 14
active antiretroviral therapy (13) 13
anti-retroviral agents - therapeutic use (13) 13
drug administration schedule (13) 13
immunodeficiency-virus type-1 (13) 13
analysis (12) 12
antiretroviral therapy, highly active (12) 12
combination therapy (12) 12
double-blind (12) 12
hiv protease inhibitors - therapeutic use (12) 12
hiv-1 - isolation & purification (12) 12
hiv-1 - physiology (12) 12
hiv-1-infected patients (12) 12
mutation (12) 12
reverse transcriptase inhibitors - adverse effects (12) 12
treatment failure (12) 12
anti-hiv agents - pharmacokinetics (11) 11
antivirals (11) 11
human-immunodeficiency-virus (11) 11
vicriviroc (11) 11
virus diseases (11) 11
adults (10) 10
benzoxazines - administration & dosage (10) 10
efficacy (10) 10
emtricitabine (10) 10
human immunodeficiency virus (10) 10
infections (10) 10
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Earth Sciences (Noranda) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Physics - Circulation Desk (1) 1
Physics - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Pereyra, Florencia and Jia, Xiaoming and McLaren, Paul J and Telenti, Amalio and de Bakker, Paul I. W and Walker, Bruce D and Ripke, Stephan and Brumme, Chanson J and Pulit, Sara L and Carrington, Mary and Kadie, Carl M and Carlson, Jonathan M and Heckerman, David and Graham, Robert R and Plenge, Robert M and Deeks, Steven G and Gianniny, Lauren and Crawford, Gabriel and Sullivan, Jordan and Gonzalez, Elena and Davies, Leela and Camargo, Amy and Moore, Jamie M and Beattie, Nicole and Gupta, Supriya and Crenshaw, Anew and Burtt, Noël P and Guiducci, Candace and Gupta, Namrata and Gao, Xiaojiang and Qi, Ying and Yuki, Yuko and Piechocka-Trocha, Alicja and Cutrell, Emily and Rosenberg, Rachel and Moss, Kristin L and Lemay, Paul and O'Leary, Jessica and Schaefer, Todd and Verma, Pranshu and Toth, Ildiko and Block, Brian and Baker, Brett and Rothchild, Alissa and Lian, Jeffrey and Proudfoot, Jacqueline and Alvino, Donna Marie L and Vine, Seanna and Addo, Marylyn M and Allen, Todd M and Altfeld, Marcus and Henn, Matthew R and Le Gall, Sylvie and Streeck, Henik and Haas, David W and Kuritzkes, Daniel R and Robbins, Gregory K and Shafer, Robert W and Gulick, Roy M and Shikuma, Cecilia M and Haubrich, Richard and Riddler, Sharon and Sax, Paul E and Daar, Eric S and Ribaudo, Heather J and Agan, Brian and Agarwal, Shanu and Ahern, Richard L and Allen, Brady L and Altidor, Sherly and Altschuler, Eric L and Ambardar, Sujata and Anastos, Kathryn and Anderson, Ben and Anderson, Val and Anady, Ushan and Antoniskis, Diana and Bangsberg, David and Barbaro, Daniel and Barrie, William and Bartczak, J and Barton, Simon and Basden, Patricia and Basgoz, Nesli and Bazner, Suzane and Bellos, Nicholaos C and Benson, Anne M and Berger, Judith and Bernard, Nicole F and Bernard, Annette M and Birch, Christopher and Bodner, Stanley J and Bolan, Robert K and Boueaux, Emilie T and Bradley, Meg and Braun, James F and Brndjar, Jon E and Brown, Stephen J and Brown, Katherine and Brown, Sheldon T and ... and The International HIV Controllers Study and Int HIV Controllers Study and International HIV Controllers Study
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2010, Volume 330, Issue 6010, pp. 1551 - 1557
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 535, Issue 7613, pp. 556 - 560
Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open... 
RESPONSES | POTENT | REPLICATION | GENETIC-DETERMINANTS | IMMUNOTHERAPY | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | SEQUENCE | ANTIRETROVIRAL THERAPY | MONOCLONAL-ANTIBODIES | Anti-HIV Agents - pharmacology | Antibodies, Neutralizing - administration & dosage | Disease Reservoirs - virology | Humans | Middle Aged | Male | Proviruses - immunology | Anti-HIV Agents - administration & dosage | Tissue Distribution | Young Adult | Antibodies, Monoclonal, Humanized | HIV Infections - immunology | Proviruses - drug effects | Antibodies, Neutralizing - immunology | HIV-1 - growth & development | HIV Antibodies - immunology | HIV Envelope Protein gp160 - chemistry | Time Factors | Antibodies, Neutralizing - therapeutic use | Binding Sites - immunology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Binding Sites - drug effects | HIV Envelope Protein gp160 - metabolism | Drug Administration Schedule | HIV-1 - drug effects | HIV Infections - virology | Broadly Neutralizing Antibodies | HIV Antibodies - administration & dosage | Viral Load - immunology | Proviruses - growth & development | HIV-1 - immunology | HIV Envelope Protein gp160 - antagonists & inhibitors | Adolescent | HIV Infections - drug therapy | Aged | HIV Envelope Protein gp160 - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Prevention | Antiviral agents | HIV antibodies | Dosage and administration | Host-virus relationships | Drug therapy, Combination | Drug therapy | Health aspects | HIV infection | Methods | Clinical trials | Antiretroviral drugs | Immunoglobulins | Human immunodeficiency virus--HIV | Binding sites
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 3/2010, Volume 201, Issue 5, pp. 662 - 671
Journal Article
Nature (London), ISSN 1476-4687, 2018, Volume 561, Issue 7724, pp. 479 - 484
....11] [sup.12], Roy M. Gulick [sup.13], Nico Pfeifer [sup.7] [sup.14] [sup.15] [sup.16], Gerd Fatkenheuer [sup.3] [sup.4], Michael S. Seaman [sup.17], Florian... 
SHIV INFECTION | PRIMARY HIV-INFECTION | RESERVOIR | DURABLE CONTROL | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | IN-VIVO | TREATMENT INTERRUPTION | T-CELLS | HUMANIZED MICE | Antibodies, Neutralizing - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Drug Resistance, Viral | Antibodies, Monoclonal - therapeutic use | Male | Phylogeny | Anti-HIV Agents - administration & dosage | Young Adult | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - adverse effects | HIV Antibodies - immunology | HIV-1 - isolation & purification | Antibodies, Neutralizing - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Antibodies, Neutralizing - adverse effects | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Antibodies, Monoclonal - immunology | Carrier State - immunology | HIV Infections - virology | Viremia - drug therapy | HIV Antibodies - administration & dosage | Carrier State - virology | HIV-1 - immunology | Viremia - virology | Antibodies, Monoclonal - administration & dosage | Viremia - prevention & control | Adolescent | Carrier State - drug therapy | HIV Infections - drug therapy | Viremia - immunology | Aged | HIV Envelope Protein gp160 - immunology | Infusions, Intravenous | Binding Sites, Antibody | Virus Activation - immunology | Virus Latency - immunology | Anti-HIV Agents - immunology | Drug Combinations | Physiological aspects | HIV patients | Care and treatment | Drug therapy, Combination | HIV antibodies | Antiretroviral drugs | Therapy | Antiviral agents | Interruption | Immunoglobulins | Viremia | Clinical trials | Viruses | Infections | Genomes | Antiretroviral therapy | Antiretroviral agents | Lymphocytes | Human immunodeficiency virus--HIV | Monoclonal antibodies | Drug therapy | Bioinformatics | Binding sites
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2009, Volume 4, Issue 5, p. e5683
Journal Article
Nature medicine, ISSN 1546-170X, 2017, Volume 23, Issue 2, pp. 185 - 191
Journal Article
Topics in Antiviral Medicine, ISSN 2161-5861, 04/2018, Volume 25, Issue 4, pp. 127 - 132
Over the past 30 years, antiretroviral drug regimens for treating HIV infection have become more effective, safer, and more convenient. Despite 31 currently... 
Fostemsavir | Integrase | Antiretroviral drugs | Cabotegravir | MK-8591 | Antiretroviral therapy | Doravirine | Entry inhibitor | Nonnucleoside | HIV | Bictegravir | Nucleoside | Investigational | Ibalizumab | entry inhibitor | bictegravir | antiretroviral therapy | nucleoside | fostemsavir | doravirine | integrase | nonnucleoside | ibalizumab | investigational | antiretroviral drugs | cabotegravir
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2008, Volume 359, Issue 14, pp. 1429 - 1441
Journal Article
Journal Article
Current Opinion in HIV and AIDS, ISSN 1746-630X, 10/2019, Volume Publish Ahead of Print, Issue 1, pp. 4 - 12
PURPOSE OF REVIEWThe purpose of this review is to summarize the current standards of care for both HIV treatment and HIV prevention in 2019. RECENT... 
Prevention | Antiviral agents | Care and treatment | Usage | HIV infection | Anti-HIV agents | Standards
Journal Article